Piper Sandler lowered the firm’s price target on Schrodinger (SDGR) to $45 from $50 and keeps an Overweight rating on the shares following quarterly results. The firm notes Schrodinger reiterated that it expects to report initial clinical data from 3 programs in 2025. Specifically, it refined guidance for SGR-1505, now expecting to report data in Q2 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDGR:
- Schrödinger, Inc. Reports Strong 2024 Financial Results
- Schrodinger’s Strong Growth Prospects and Buy Rating Driven by Robust Drug Discovery and Software Performance
- Schrodinger sees FY25 software revenue growth up 10%-15%
- Schrodinger reports FY24 EPS ($2.57) , two estimates ($2.59)
- SDGR Upcoming Earnings Report: What to Expect?